Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Picking Winners in the Projected $75 Billion Cannabis Industry

IIPR

HENDERSON, NV / ACCESSWIRE / April 12, 2019 / The Cowen Group has projected that the cannabis industry will see $75 billion in global annual sales by 2030, up from a previous forecast of $50 billion by 2026. We are looking for companies poised to get a large piece of this pie.

That's why we're highlighting THC Therapeutics, Inc. (THCT). The US patent office has accepted ALL 20 claims for The dHydronator®. Very recently, the company announced that it has received patent protection for the dHydronator®, which can reduce moisture content of cannabis to 10% in only 10-14 hours, which normally it takes up to 14 days. The dHydronator® also destroys harmful surface contaminants & pathogens. The term of the patent provides 20 years of protection on the scalable intellectual property for the dHydronator®. This is Big news from THCT.

Today we are highlighting: THC Therapeutics, Inc. (THCT), Innovative Industrial Properties, Inc. (IIPR), Aphria, Inc. (APHA), iAnthus Capital Holdings, Inc. (ITHUF) and Altria Group, Inc. (MO).

THC Therapeutics, Inc. (THCT) (Market Cap: $136.241M; Share Price: $10.20) has developed a sanitizing herb dryer, The dHydronator®. Their laboratory-proven product is specifically designed for drying and sanitizing freshly harvested cannabis and herbs. THCT's product has been tested by two independent laboratories. The testing covered over 6 strains and 9 independent tests to confirm the findings.

As we mentioned earlier, the US patent office has accepted ALL 20 claims for The dHydronator®. The company has received patent protection for the dHydronator®. Start your research today on (THCT)

________

Innovative Industrial Properties, Inc. (IIPR) (Market Cap: $824.014M; Share Price: $84.03), the first and only real estate company on the New York Stock Exchange focused on the regulated U.S. cannabis industry, announced results for the company's fourth quarter and year ended December 31, 2018. Last year represented the second full year since IIP commenced real estate operations and completed its initial public offering in December 2016. Per the details of their results, as of March 13, 2019, the company owned 13 properties that were 100% leased to state-licensed medical-use cannabis operators and comprising an aggregate of approximately 1,128,000 rentable square feet (including approximately 159,000 rentable square feet under development/redevelopment) in Arizona, California, Colorado, Illinois, and several other state.

Innovative Industrial Properties, Inc. is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated medical-use cannabis facilities. Innovative Industrial Properties, Inc. has elected to be taxed as a real estate investment trust, commencing with the year ended December 31, 2017.

________

Aphria, Inc. (APHA) (Market Cap: $2.454B; Share Price: $9.81) announced on Friday that its German subsidiary, Aphria Deutschland GmbH, has been selected by the German Federal Institute for Drugs and Medical Devices to receive a license for the domestic cultivation of medical cannabis. The provisional decision announced by BfArM is subject to a mandatory 10-day standstill period for public contracts, which permits unsuccessful bidders to challenge the decision before the final contract is signed.

Today, Viridium Pacific Group Ltd. ("Viridium" or the "Company") (TSXV:VIR) (OTC PINK: VIRFF) had announced that its wholly owned subsidiary, EFX Laboratories Inc. ("EFX"), a contract manufacturer of cannabis oil capsules, has commenced medical two-piece capsule sales through its partnership with Broken Coast Cannabis Ltd. ("BCC"), a wholly owned subsidiary of Aphria Inc. ("Aphria") (TSX: APHA and NYSE:APHA) available to BCC medical clientele via their online sales portal. Under the terms of the agreement between EFX and Aphria, the agreement enables EFX to provide commercial manufacturing services with a revenue sharing structure on the medical two-piece capsule containing various THC and CBD concentrations.

Aphria Inc. produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc. is headquartered in Leamington, Canada.of anti-cancer medication, as well as ornamental bonsai trees for purifying indoor air quality.

________

iAnthus Capital Holdings, Inc. (ITHUF) (Market Cap: $658.994M; Share Price: $4.6275) which owns, operates, and partners with leading cannabis operators across the U.S. last week announced that it has entered into a licensing agreement with Blissiva, a women-owned, Maryland-based company specializing in producing and distributing medical cannabis products specifically formulated for women.

Per the licensing agreement, iAnthus will manufacture, market and sell a variety of Blissiva products in its markets, with an initial launch in Maryland scheduled for April 20, 2019. Additionally, iAnthus has the exclusive right to launch Blissiva in its ten other existing states and across the United States.

Falcon Technologies, Inc. is a nutraceutical company developing a range of CBD-based products. The company's mission is to employ best practice science to source, manufacture and package all its CBD products from within the United States. The company performs farm site visits and manufacturing site visits and sources its products from only the highest quality hemp farms and processors in North America. The company also aims to launch a line of CBD products specially formulated for animals by the end of 2019.

________

Altria Group, Inc. (MO) (Market Cap: $104.704B; Share Price: $55.98) announced this week that it has received a request for additional information (Second Request) from the U.S. Federal Trade Commission relating to its investment in JUUL Labs, Inc. that closed in December 2018.

Altria currently holds an approximate 35% non-voting, economic interest in JUUL. Altria is now seeking to convert its JUUL interest to voting securities pursuant to the terms of its investment. Following conversion, Altria expects to account for its investment in JUUL under the equity method of accounting and will have the right to designate one-third of the members of JUUL's board of directors. JUUL will remain fully independent.

Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, smokeless products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand, cigars principally under the Black & Mild brand, and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands. The company also produces and sells varietal and blended table wines, and sparkling wines.

Altria's wholly-owned subsidiaries include Philip Morris USA Inc. (PM USA), U.S. Smokeless Tobacco Company LLC (USSTC), John Middleton Co. (Middleton), Sherman Group Holdings, LLC and its subsidiaries (Nat Sherman), Ste. Michelle Wine Estates Ltd. (Ste. Michelle) and Philip Morris Capital Corporation (PMCC). Altria holds equity investments in Anheuser-Busch InBev SA/NV (AB InBev), JUUL Labs, Inc. (JUUL) and Cronos Group Inc. (Cronos Group).

________

Signed by

Priyanka Goel, CFA

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a three-month term consulting agreement with THCT dated 2/14/18. The agreement calls for 50,000 restricted shares of THCT per month. This agreement has been amended to $20,000 per month, and 55,000 shares per month and extended for twelve months ending 3/18/2020. All payments were made directly by THC Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. THCT was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Full Legal Disclaimer Click Here.

Contact Information:

Company Name: ACR Communication LLC.

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

SOURCE: ACR Communication LLC.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today